HDAC Inhibitors for the Treatment of Pulmonary Arterial Hypertension

OCR Number: 
OCR 6370
  • The transcription factor myocyte enhancer factor 2 (MEF2) is significantly impaired in pulmonary arterial hypertension (PAH).
  • Inhibition of class IIa HDACs restored MEF2 activity in pulmonary arterial endothelial cells (PAECs), as demonstrated by increased expression of targets, including miR-424 and miR-503.
  • Augmentation of MEF2 activity holds a potential therapeutic value in PAH.
  • Selective HDAC IIa inhibition was identified as a viable alternative approach to avoid the potential adverse effects of broad spectrum HDAC inhibition in PAH.
IP Status: 
PCT filed
Kim, J., Hwangbo, C., Hu, X., Kang, Y., Papangeli, I., Mehrotra, D., … & Chun, H. J. (2014). Restoration of impaired endothelial MEF2 function rescues pulmonary arterial hypertension. Circulation, CIRCULATIONAHA-114. [Pub Med]
Licensing Contact: